The Company will also present at the BioEurope, Annual Vascular Interventional Advances and Cell and
Gene Therapy Manufacturing conferences, all held in November
HAIFA, Israel, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company
developing novel placenta-based cell therapy products, today announced that the Company will be presenting at four conferences
during November: at the BioEurope conference, which is being held November 5–7, 2018 in Copenhagen, at the 15th Annual
Vascular Interventional Advances (VIVA) Conference, which is being held November 5-8 in Las Vegas, at the 2018 American Heart
Association (AHA) Scientific Sessions, which are being held November 10-12 in Chicago and the Cell and Gene Therapy Manufacturing
conference, which is being held November 14-15 in London.
At the AHA Scientific Sessions, Prof. Norbert Wiess, the Principal Investigator of the Company’s Phase II
intermittent claudication (IC) study, will present detailed results from the study. The presentation will be held on Saturday,
November 10, 2018 from 9:00-10:15am. In June 2018, the Company announced positive top-line results from its multinational Phase II
clinical study of PLX-PAD cells in the treatment of IC. Data demonstrated PLX-PAD’s ability to reduce the incidence of
revascularization and improved patients’ mobility. Study results also validate the design of Pluristem’s ongoing pivotal Phase III
study in critical limb ischemia (CLI), a more severe stage of PAD.
At the VIVA Conference, during the Disruptive Technology session, Pluristem will present an overview of its
off-the-shelf, placenta-derived cell therapy technology and development plans for its lead cell therapy candidate, PLX-PAD, for the
treatment of peripheral artery disease (PAD). The presentation will be held on Wednesday, November 7, 2018 from 8:15-9:15am.
At the BioEurope conference, during the cell and gene track, Pluristem will present an overview of its cell
therapy products and clinical development. The presentation will be held on Tuesday, November 6, 2018, from 10:00-11:00am.
At the Cell and Gene Therapy Manufacturing conference, Pluristem will present an overview of its in-house
manufacturing process. The presentation will be held on Thursday, November 15, 2018 from 9:10-9:50am.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy products. The
Company has reported robust clinical trial data in multiple indications for its patented PLX cells and is entering late stage
trials in several indications. PLX cell products release a range of therapeutic proteins in response to inflammation, ischemia,
muscle trauma, hematological disorders, and radiation damage. The cells are grown using the Company's proprietary three-dimensional
expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong
intellectual property position; Company-owned and operated, GMP-certified manufacturing and research facilities; strategic
relationships with major research institutions; and a seasoned management team.
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the Private Securities
Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluristem is using forward-looking statements
when it discusses the timing, description and results of its clinical studies and its belief that the PLX-PAD study results
validate the design of its ongoing Phase III study in CLI. These forward-looking statements and their implications are based on the
current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the forward-looking statements. The following factors, among others,
could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and
market requirements; Pluristem may encounter delays or obstacles in launching and/or successfully completing its clinical trials;
Pluristem’s products may not be approved by regulatory agencies, Pluristem’s technology may not be validated as it progresses
further and its methods may not be accepted by the scientific community; Pluristem may be unable to retain or attract key employees
whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Pluristem’s
process; Pluristem’s products may wind up being more expensive than it anticipates; results in the laboratory may not translate to
equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical
trials; Pluristem’s patents may not be sufficient; Pluristem’s products may harm recipients; changes in legislation may adversely
impact Pluristem; inability to timely develop and introduce new technologies, products and applications; loss of market share and
pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ
materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no
obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties
affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange
Commission.
Contact:
Efrat Kaduri
Head of Investor and Public Relations
972-74-7108600
efratk@pluristem.com
Karine Kleinhaus, MD, MPH
Divisional VP, North America
1-914-512-4109
karinek@pluristem.com
